Abstract
Background: Valproic acid (VPA) and topiramate (TPM), initially developed as antiepileptics, are approved for migraine prophylaxis in adults but not children. The differences in their antimigraine mechanism(s) by age remain unclear.Methods: A migraine model induced by intra-cisternal (i.c.) capsaicin instillation in pediatric (4–5 weeks) and adult (8–9 weeks) rats was pretreated with VPA (30, 100 mg/kg) or TPM (10, 30, 100 mg/kg). Noxious meningeal stimulation by the irritant capsaicin triggered trigeminovascular system (TGVS) activation mimicking migraine condition, which were assessed peripherally by the depletion of calcitonin gene-related peptide (CGRP) in sensory nerve fibers of the dura mater, the increased CGRP immunoreactivity at trigeminal ganglia (TG) and centrally by the number of c-Fos-immunoreactive (c-Fos-ir) neurons in the trigeminocervical complex (TCC). Peripherally, CGRP released from dural sensory nerve terminals of TG triggered pain signal transmission in the primary afferent of trigeminal nerve, which in turn caused central sensitization of the TGVS due to TCC activation and hence contributed to migraine.Results: In the VPA-treated group, the central responsiveness expressed by reducing the number of c-Fos-ir neurons, which had been increased by i.c. capsaicin, was significant in pediatric, but not adult, rats. Inversely, VPA was effective in peripheral inhibition of elevated CGRP immunoreactivity in the TG and CGRP depletion in the dura mater of adult, but not pediatric, rats. In TPM group, the central responsiveness was significant in both adult and pediatric groups. Peripherally, TPM significantly inhibited capsaicin-induced CGRP expression of TG in adult, but not pediatric, rats. Interestingly, the capsaicin-induced depletion of CGRP in dura was significantly rescued by TPM at high doses in adults, but at low dose in pediatric group.Conclusion: These results suggest VPA exerted peripheral inhibition in adult, but central suppression in pediatric migraine-rats. In contrast, TPM involves both central and peripheral inhibition of migraine with an optimal therapeutic window in both ages. These findings may clarify the age-dependent anti-migraine mechanism of VPA and TPM, which may guide the development of new pediatric anti-migraine drugs in the future.
Highlights
As compared with adult migraine (12–17%) (Stewart et al, 1994; Wang, 2003), pediatric migraine is characterized by more bilateral involvement, shorter duration, less severity, better response to treatment (Swaiman et al, 1999), and lower prevalence (6–11%) (Abu-Arefeh and Russell, 1994; Wang et al, 2005)
We found that pediatric rats had a comparable central responsiveness, measured by the number of activated trigemino-cervical complex (TCC) neurons, as adult rats, but displayed less peripheral responsiveness than adults, including the CGRP immunoreactivity (CGRP-ir) in the trigeminal ganglia (TG) and CGRP depletion in the dura mater (Fan et al, 2012)
This suggests that the central responsiveness, expressed by c-Fos-ir neurons in TCC, to Valproic acid (VPA) is only significant at a high dose in pediatric rats, but not in adult rats even at high does
Summary
As compared with adult migraine (12–17%) (Stewart et al, 1994; Wang, 2003), pediatric migraine is characterized by more bilateral involvement, shorter duration, less severity, better response to treatment (Swaiman et al, 1999), and lower prevalence (6–11%) (Abu-Arefeh and Russell, 1994; Wang et al, 2005). In a rat migraine model induced by intra-cisternal (i.c.) instillation of capsaicin, we have compared differences in central and peripheral responsiveness of the TGVS between pediatric and adult rats (Fan et al, 2012). We found that pediatric rats had a comparable central responsiveness, measured by the number of activated TCC neurons, as adult rats, but displayed less peripheral responsiveness than adults, including the CGRP immunoreactivity (CGRP-ir) in the TG and CGRP depletion (inversely reflected by CGRP-ir) in the dura mater (Fan et al, 2012). Valproic acid (VPA) and topiramate (TPM), initially developed as antiepileptics, are approved for migraine prophylaxis in adults but not children. The differences in their antimigraine mechanism(s) by age remain unclear
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
